1. Home
  2. MITT vs IKT Comparison

MITT vs IKT Comparison

Compare MITT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MITT

AG Mortgage Investment Trust Inc.

HOLD

Current Price

$7.76

Market Cap

244.9M

Sector

Real Estate

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

215.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITT
IKT
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.9M
215.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MITT
IKT
Price
$7.76
$1.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$9.25
$5.00
AVG Volume (30 Days)
137.1K
673.0K
Earning Date
04-29-2026
03-26-2026
Dividend Yield
11.96%
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.48
N/A
Revenue Next Year
$5.06
N/A
P/E Ratio
$9.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.86
$1.33
52 Week High
$9.27
$2.26

Technical Indicators

Market Signals
Indicator
MITT
IKT
Relative Strength Index (RSI) 51.69 44.94
Support Level $7.46 $1.64
Resistance Level $7.95 $1.76
Average True Range (ATR) 0.16 0.07
MACD 0.01 -0.00
Stochastic Oscillator 70.71 40.54

Price Performance

Historical Comparison
MITT
IKT

About MITT AG Mortgage Investment Trust Inc.

TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: